RE:RE:RE:I read about increased short volume….not a good place Man you guys here are disappointing me..........
The source was the May quarterly.
"
"To conclude my section of the call, I'll speak briefly about our preclinical CAR T program. Building off Tom's earlier remarks, having been heartened by the positive data from the work we've done with Dr. Vile in the Mayo Clinic, we are advancing research collaborations of biotech companies interested in validating or recapitulating the results from the Science Translational Medicine publication.
One of these companies has already produced results with Pela in combination with their own CAR T constructs that are in-line with what was seen previously in Dr. Vile's work. That company is now repeating those results to ensure their accuracy and we look forward to reviewing them with our research partner in the second half of the year. Recapitulating the Science Translational Medicine results is an important step for our collaborator because unlike other agents, a class effect cannot be assumed that CAR T cells since they behave according to their specific genetic makeup. We look forward to providing more information on CAR T work with Mayo at the upcoming ASCO meeting"